More good news - Femara helps prevent the return of breast cancer

Download PDF Copy

Dec 14 2005

In more good news for women suffering from breast cancer a study by the the Swiss drugmaker Novartis has shown that their drug Femara benefits women with hormone-sensitive early breast cancer.

The drug company says that postmenopausal women who switched from a placebo to Femara experienced a 69-percent reduction in the risk of their breast cancer returning.

The new data has been presented at the 28th annual San Antonio Breast Cancer Symposium in Texas and is the first time that an aromatase inhibitor has shown a benefit in starting therapy up to five years after the end of standard Tamoxifen treatment.

Posted in: Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

Study brings hope for a more personalized approach to treat ER+ breast cancer

New method uncovers how extracellular vesicles impact immune response in cancer

Plant-derived carotenoid found to boost immune response against cancer

Study finds minimal risk of second cancer in breast cancer survivors

Study provides evidence for a causal genetic link between prostate cancer and urothelial carcinoma

Diabetes-altered blood particles suppress immune defense in breast cancer

Eating more animal protein may slightly lower cancer mortality

High protein diet linked to increased risk of cancer-associated venous thromboembolism

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.